The primary metabolizer of bradykinin is ACE1, and one of the breakdown products, des-Arg9-bradykinin, is further metabolized by ACE2 [15-17]. Impairment in this metabolic pathway can lead to an accumulation of bradykinin, resulting in increased vascular permeability and angioedema (Figure 1B). This evidence concerns the gene ACE and angioedema.